Eli Lilly to acquire Calytrix Bio in deal worth up to $1.5 billion

Eli Lilly to acquire Calytrix Bio in deal worth up to $1.5 billion
Lilly expands in hematology

Eli Lilly is expanding its push beyond its core diabetes and weight-loss business with an agreement to buy Calytrix Bio for up to $1.5 billion in cash. The transaction is aimed at advancing treatments for rare blood cancers and broadening Lilly's presence in hematology.

Highlights

  • Eli Lilly will acquire Calytrix Bio in a deal valued up to $1.5 billion, with undisclosed upfront and milestone-linked payments.
  • Calytrix's early-stage antibody for essential thrombocythemia and myelofibrosis expands Lilly's experimental portfolio in rare blood disorders.
  • The acquisition strengthens Lilly's hematology business beyond Jaypirca and diversifies its pipeline away from diabetes and obesity therapeutics.

Deal structure and pipeline expansion

As reported by Reuters, citing Calytrix Bio, the acquisition includes an upfront payment and additional cash payouts tied to clinical trial and regulatory milestones. The privately held biotech does not disclose the size of the upfront payment or when the transaction is expected to close.

Calytrix's lead candidate is an early-stage antibody treatment being developed for essential thrombocythemia and myelofibrosis, rare blood disorders that cause the bone marrow to produce excessive abnormal blood cells. The asset gives Lilly another experimental medicine in an area where targeted treatments remain in demand.

Hematology growth and portfolio diversification

The agreement marks the latest in a series of acquisitions by the Indianapolis-based drugmaker as it works to diversify its revenue base beyond blockbuster diabetes and obesity medicines, which remain its main growth engine. Adding Calytrix also strengthens Lilly's footprint in hematology, a business that already includes the FDA-approved blood cancer drug Jaypirca.

The move underscores how large pharmaceutical groups continue to use dealmaking to add earlier-stage biotech assets in specialized disease areas. For Lilly, the Calytrix purchase deepens its pipeline in rare blood disorders while potentially creating another long-term growth avenue outside its highest-selling franchises.

We have previously detailed the potential Ollin Biosciences deal as another example of big-pharma biotech dealmaking.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.